Vernal keratoconjunctivitis

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

Retrieved on: 
Thursday, February 15, 2024

Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.

Key Points: 
  • Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.
  • View the full release here: https://www.businesswire.com/news/home/20240215859659/en/
    “We are pleased to enter the Canadian market through this partnership with Apotex, which has a proven track record of success serving Canadian eyecare professionals and their patients,” said Mark L. Baum, Chairman and Chief Executive Officer of Harrow.
  • And for products, Apotex will pursue approval for in Canada:
    VEVYE (cyclosporine ophthalmic solution) 0.1%, a novel water-free vehicle (perfluorobutylpentane) based on semifluorinated alkanes, indicated to treat the signs and symptoms of dry eye disease.
  • ZERVIATE (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Retrieved on: 
Tuesday, October 24, 2023

NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.

Key Points: 
  • NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
  • ZERVIATE® (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for treating ocular itching associated with allergic conjunctivitis.
  • Harrow announced its acquisition of the U.S. commercial rights of these products in July of 2023.
  • To date, Harrow has been receiving profit transfers on these products; however, with the transfer of the NDAs completed, Harrow has launched these products in the U.S. under the Harrow name.

Competitive Landscape in 2023 Conjunctivitis Treatment Market Features Key Players like Novartis, Allergan, and More - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 17, 2023

The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.

Key Points: 
  • The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.
  • Thus the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period.
  • The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.
  • The conjunctivitis treatment market is moderately consolidated in nature due to the presence of several companies operating globally as well as regionally.

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

Retrieved on: 
Tuesday, July 18, 2023

NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.

Key Points: 
  • NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
  • VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults and holds orphan-drug exclusivity.
  • ZERVIATE® (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.
  • VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children from four years of age through adolescence.

Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America

Retrieved on: 
Tuesday, July 18, 2023

Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Key Points: 
  • Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
  • Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI®.
  • Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia® and Cationorm® Plus.

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 10, 2022

During the third quarter of 2022, the Company also disclosed an additional target and further indications for its ETF gene therapy program.

Key Points: 
  • During the third quarter of 2022, the Company also disclosed an additional target and further indications for its ETF gene therapy program.
  • Cash Position: As of September30, 2022, cash and cash equivalents was $68.8 million, compared to $104.9 million as of June 30, 2022.
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • The tender offer for the outstanding common stock of Oyster Point Pharma Inc. (OP) has not yet been commenced.

Global Allergic Conjunctivitis Market Report (2022 to 2027) - Players Include Ocular Therapeutix, Portola Pharmaceuticals and Alcon - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022

Recently, the prevalence of allergic conjunctivitis has increased due to factors like rapid urbanization and an increasing number of allergens.

Key Points: 
  • Recently, the prevalence of allergic conjunctivitis has increased due to factors like rapid urbanization and an increasing number of allergens.
  • United States dominates Global Allergic Conjunctivitis Market, Patients Population & Treated Patients Population
    As per our analysis, the United States stands out as the largest market for allergic conjunctivitis treatments due to the high prevalence of allergic conjunctivitis.
  • Our report covers numerous Disease Type variants like Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC), and Giant Papillary Conjunctivitis (GPC).
  • The increase in awareness of allergic conjunctivitis associated with medical treatment & upcoming therapies is enhancing the market expansion.

Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

Retrieved on: 
Monday, May 2, 2022

We are proud to make Verkazia available for all those with VKC in the United States who have lacked optimal treatment options for this condition.

Key Points: 
  • We are proud to make Verkazia available for all those with VKC in the United States who have lacked optimal treatment options for this condition.
  • In addition, having a treatment option for the rare disease VKC will strengthen our existing product portfolio for ocular surface disease in the United States.
  • Worldwide, Verkazia is available for the treatment of VKC in the United States, Canada, and select countries across Asia and Europe.
  • Verkazia (cyclosporine ophthalmic emulsion) 0.1% is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

Investigation Report on China's Tacrolimus Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022

The "Investigation Report on China's Tacrolimus Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Tacrolimus Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • In light of research findings, the indication for preventing rejection in transplantation operations generates the most sales for Tacrolimus.
  • In addition to Astellas, other manufacturers in the Chinese Tacrolimus market are Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.
  • 2 Sales of Tacrolimus in China, 2016-2020
    2.3 Sales of Tacrolimus by Dosage Form in China, 2016-2020

Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program

Retrieved on: 
Monday, October 25, 2021

The article in Allergy summarizes a large body of work undertaken with University College of London and Moorfields Eye Hospital.

Key Points: 
  • The article in Allergy summarizes a large body of work undertaken with University College of London and Moorfields Eye Hospital.
  • MMP shares a similar pathology with bullous pemphigoid where Akari has initiated a Phase III study with nomacopan.
  • Clive Richardson, Chief Executive Officer of Akari, commented, The new surface of the eye data is an important step forward in our program and highlights the potential benefits of nomacopans differentiated bi-specific mode of action.
  • Taken together with prior data this collectively points to the more severe form of these diseases as important clinical targets for nomacopan within the $6bn+ surface of the eye market.